We compared fluorescence in situ hybridization (FISH) 
HER-2 is a proto-oncogene located on the long arm of chromosome 17 encoding a 185-kd transmembrane tyrosine kinase growth factor receptor closely related to epidermal growth factor receptor. HER-2 expression stimulates growth and cellular motility. 1, 2 HER-2 protein overexpression is seen in 10% to 35% of human breast cancers and is associated with amplification of the gene in more than 96% of cases. [3] [4] [5] HER-2 protein overexpression is associated with a poorer outcome for women with node-positive 6 and node-negative lesions. [7] [8] [9] HER-2 overexpression frequently is seen in ductal carcinoma in situ of the comedo type. 10, 11 It is not found in neuroendocrine carcinomas. 11, 12 HER-2 overexpression might be associated with reduced or even adverse response to antihormonal therapy. 13, 14 It also might be associated with resistance to certain types of adjuvant chemotherapy and an enhanced response to others.
Treatment with monoclonal antibodies against HER-2 might increase the response rate in combination with chemotherapy, and the time to disease progression and survival of patients with metastatic disease might be prolonged. 3, 15, 16 Thus, in addition to being a prognostic indicator, HER-2 overexpression and amplification are important in determining treatment strategies. Furthermore, because the degree of overexpression and amplification is associated with survival and response to treatment, accurate, reproducible quantification is essential. 17 The aim of this study was to compare methods of quantification of HER-2 amplification and expression in breast carcinoma by using the following: (1) fluorescence in situ hybridization (FISH) with probes for the HER-2 gene and chromosome 17 performed on fine-needle aspirate (FNA)
Materials and Methods
The material in this study comprised 49 cases of breast carcinoma referred for FNA at the Breast Diagnostic Center at St Olav's Hospital, Trondheim, Norway. All 49 cases were examined for HER-2 gene amplification by means of FISH performed on cytologic smears obtained by routine FNA at the clinic and on formalin-fixed, paraffin-embedded tissue samples from 34 of these cases. HER-2 protein expression was examined by means of immunohistochemical analysis performed on sections from formalin-fixed, paraffinembedded tumor tissue samples in 39 of these cases, and immunocytochemical analysis was done on air-dried FNA smears in 46 of them. TaqMan RT-PCR for HER-2-mRNA was performed on 48 cases (including a control case of gynecomastia) using RNA extracted from FNA smears. PCR relative quantification for HER-2 DNA was done in 34 cases using DNA extracted from the same tumors. The results were evaluated independently and then compared.
Fluorescence In Situ Hybridization

FISH on FNA Smears
The FNA smears were made during routine investigation of the tumors at the Breast Diagnostic Center. The unstained smears had been air dried for from 1 to 4 hours and then stored at -80°C for up to 4 years before the study. FISH for HER-2 amplification was performed on FNA smears using the PathVysion (Abbott, Fornebu, Norway) HER-2/chromosome 17 DNA probe kit, and modifications of published procedures and the manufacturer's instructions were followed.
Briefly, the air-dried smears were retrieved from storage at -80°C and fixed in glacial acetic acid/methanol (1:3) for 40 minutes at -20°C. The slides then were dehydrated (70%, 80%, and 100% ethanol, 1 minute in each) and permitted to dry. Before drying, the unstained smears were examined in a phase-contrast microscope to select an area of the smear suitable for hybridization. An area was considered suitable if it contained an adequate number of tumor cells with minimal overlapping. The edges of the smears were avoided because of the danger of artifacts in this area. An EasiSeal frame (Hybaid, Ashford, England) was used, and 10 µL of SpectrumGreen-labeled chromosome enumeration probe 17 (CEP17) and SpectrumOrange-labeled HER-2/neu probe (Abbott) was applied to the smears before denaturing at 72°C for 5 minutes and hybridization at 37°C overnight in a Perkin-Elmer In Situ Thermal Cycler (Applied Biosystems). Posthybridization washes were done (2 minutes in 2× standard saline citrate/0.3 NP40 lysis buffer, pH 7.2, at 72°C [± 1°C]) before dehydration (in 70%, 80%, and 100% ethanol). The smears were dried for 5 minutes at 60°C before 10 µL of DAPI (4',6-diamidino-2-phenylindole) (blue fluorescence, Abbott) contrast stain was applied.
After coverslips were applied, the smears were examined and photographed using a Nikon E600 fluorescence microscope (Nikon, Tokyo, Japan) with a filter wheel and Cytovision software (Applied Imaging, Newcastle upon Tyne, England).
FISH on Histologic Sections
There was sufficient material available for FISH on histologic sections in 34 cases. Areas suitable for hybridization were located by microscopic examination of H&E-stained sections from the same paraffin blocks. The PathVysion HER-2/chromosome 17 DNA probe kit was used according to the manufacturer's instructions. The hybridized sections were examined and photographed as described in the preceding section.
Signal Counting and Ratio Calculation
The number of CEP17 and HER-2 signals in each of 100 nuclei were counted, and an informative result was defined as an abnormal result for chromosome 17, HER-2, or both in 60% or more of the nuclei. 18 The ratio between HER-2 and chromosome 17 was calculated and recorded.
Hybridization Efficiency
A high hybridization rate was achieved in undamaged nuclei in single cells or monolayer-like aggregates of cells in which it would be reasonable to expect that the probe would be able to penetrate. We did not expect to find successful hybridization in thick aggregates of tumor cells.
Immunohistochemical and Immunocytochemical Analyses
The commercially available immunohistochemical staining kit, HercepTest (DakoCytomation, Copenhagen, Denmark), and the DAKO Autostainer (DakoCytomation) were used for staining the histologic sections and the corresponding cytologic smears. The manufacturer's instructions were followed for antigen retrieval and staining the histologic sections. The air-dried cytologic smears were retrieved from -80°C, thawed for a few minutes, and placed for 15 minutes in formalin, 5 minutes in phosphate-buffered saline, 4 minutes in methanol, and 2 minutes in acetone. After air drying briefly, they were rinsed twice for 5 minutes each time in phosphate-buffered saline. Staining was done in the Autostainer according to the procedure recommended for histologic sections. After coverslips were applied, the sections and smears were examined in the microscope independently, and the staining intensity was graded as 0, 1+, 2+, or 3+ according to the guidelines accompanying the HercepTest kit.
RNA Extraction and TaqMan RT-PCR
TaqMan RT-PCR was performed on total RNA extracted from air-dried FNA smears. The smears had been stored at -80°C for up to 4 years before analysis. Total RNA was extracted using the Qiagen RNeasy Mini Kit extraction procedure (Qiagen, Crawley, England). Briefly, the cellular material was washed from the glass slide into 600 µL of RLT lysis buffer (included in the RNeasy kit) containing β-mercaptoethanol. The lysate was homogenized using QIAshredder columns (Qiagen) and the RNA extracted according to the manufacturer's instructions. Total RNA was eluted in 50 µL of RNase-free water and stored at -80°C until required.
The TaqMan reverse transcription assay was performed on an ABI Prism 7700 Sequence Detection System (Applied Biosystems) using a TaqMan EZ RT-PCR Kit (Applied Biosystems). HER-2 TaqMan RT-PCR primers and probes were designed from the National Center for Biotechnology Information GenBank using Primer Express Software, version 2.0. (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) TaqMan control reagents (Applied Biosystems) were used to amplify the GAPDH housekeeping gene for relative quantitation.
TaqMan RT-PCRs were performed using the TaqMan EZ RT-PCR Kit according to the manufacturer's guidelines. A 300-nmol/L concentration of HER-2 primers and a 100-nmol/L concentration of the HER-2 TaqMan probe (VIClabeled [Applera, Norwalk, CT]) were used per 25 µL of PCR reaction, and 50 to 100 ng of RNA template was added per 25 µL of PCR reaction. All PCRs were performed in duplicate. AmpErase Uracil N glycosylase (included in the TaqMan kit) was used in each PCR to prevent contamination. Human Control RNA (Applied Biosystems) was used as the positive control. RNA extracted from an FNA smear from a case of gynecomastia was used as the calibrator for the relative quantitation. No template controls were also included in each run. TaqMan RT PCRs were performed under the following thermocycling conditions: 50°C for 2 minutes, 58°C for 30 minutes, and 95°C for 5 minutes followed by 40 cycles of 94°C for 20 seconds and 60°C for 1 minute.
Relative Quantitation
Relative quantitation was used to assess the expression of HER-2 mRNA. The results were normalized to the GAPDH endogenous control and reported as a fold change relative to a calibrator sample. An FNA smear from a case of gynecomastia was used as the calibrator because gynecomastia normally does not show amplification or overexpression of HER-2. 19 The comparative Ct method 20 for relative quantitation calculated from the threshold cycle (Ct) values generated during PCR was used. The following equation was used:
Relative Quantity = 2 -∆∆Ct The ∆Ct is calculated by normalizing the Ct of the target sample with the Ct of the endogenous control (Ct target -Ct endogenous control). The ∆∆Ct then is calculated by subtracting the average ∆Ct for the calibrator sample from the corresponding average ∆Ct for the target sample. The relative levels of the target protein expression are expressed as a fold change relative to the calibrator sample. A relative quantity of 1 indicates no change in expression levels.
PCR DNA Assay
DNA was extracted from 15-µm-thick sections from the formalin-fixed, paraffin-embedded tumor tissue samples. The sections were mixed with 1 mL of xylene and centrifuged at 13,000 rpm twice for 3 minutes each time. One milliliter of absolute alcohol was added to the supernatant and centrifuged at 13,000 rpm twice 3 minutes each time. The material was dried in a DNA minivacuum centrifuge before 50 to 350 µL of Proteinase K (200 µg/mL) was added, and the mixture was kept at 37°C overnight in a Thermomixer at 700 rpm (Eppendorf, Hamburg, Germany). The protocol for the KingFisher Genomic DNA purification system was followed as described by the manufacturer (KingFisher Genomic DNA Purification Kit, ThermoLabsystems, Helsinki, Finland). PCR was performed in a LightCycler (Roche, Mannheim, Germany) using an HER-2/neu DNA Quantification Kit (Roche) according to the manufacturer's instructions. The calculation of the relative amount of HER-2 was performed by the LightCycler Relative Quantification Software (Roche Molecular Biochemicals) and expressed as a ratio to the reference gene and calibrator inherent in the kit. A ratio of 2.0 or more was considered positive, and less than 2.0 was considered negative.
Histologic Grade
There were 39 cases for which tissue biopsy specimens were available. The tumors were graded histologically according to the guidelines recommended by the Norwegian Breast Cancer Group based on the Bloom-Richardson grading system. 21, 22 
Statistics
The χ 2 test was used to test the significance of the results.
Results
The results are given in ❚Table 1❚ and ❚Table 2❚, and examples of the different techniques are shown in ❚Image 1❚, ❚Image 2❚, ❚Image 3❚, ❚Image 4❚, ❚Image 5❚, ❚Image 6❚, ❚Image 7❚, and ❚Image 8❚.
Histologic Grade
Three cases were classified as histologic grade 1, 13 as grade 2, and 23 as grade 3. The small number of grade 1 tumors probably can be explained by the fact that the cases in this study were from FNA material, and the cell yield from grade 1 tumors often is less abundant, leaving little for special tests.
Fluorescence In Situ Hybridization
FISH was performed on FNA smears from all 49 cases. Of the 49 cases, 11 had HER-2/chromosome 17 ratios greater than 2.0, indicating amplification. Of these, 9 had an immunohistochemical score of 3+, 2 had an immunocytochemical score of 2+, 9 had an increased HER-2 mRNA level, and 10 had an increased HER-2 DNA level. There was complete agreement in results for all 5 tests in 8 of 11 cases. In case 6, immunocytochemical analysis was missing, but there was complete agreement in the results of the other 4 tests. The HER-2 ratio was less than 1.0 in 7 cases. In 6 of these cases, chromosome 17 polysomy was present. Five cases had lower signal counts for HER-2 than for chromosome 17. All of these were polysomic for chromosome 17.
The HER-2/chromosome 17 ratios resulting from FISH performed on histologic sections from 34 of 49 cases showed good correlation with the results of FISH on FNA smears. Of 11 cases showing increased FISH ratios on FNA smears, 9 were histologic grade 3, and the remaining 2 were grade 2. In some cases, the number of chromosome 17 centromeres was slightly lower in the histologic section than in the corresponding FNA smear. The number of fluorescent signals per nucleus in tissue sections frequently was slightly lower than in the corresponding FNA smear. However, this led to a difference in the gene/chromosome ratio of clinical significance in only 1 case (case 35) in which the lower number of chromosome 17 centromere signals in the tissue section resulted in a FISH ratio implying true gene amplification, whereas FISH performed on the corresponding FNA smear showed polysomy. 23 
Immunohistochemical Analysis
Of 39 cases for which biopsy material was available, 9 showed 3+ immunostaining on the histologic sections. All 9 cases showed amplification of the HER-2 gene, with FISH ratios ranging from 2.5 to 7.5.
Twelve cases had an immunohistochemical score of 2+; however, only 1 of them showed gene amplification. Six showed chromosome 17 polysomy but not gene amplification. The level of HER-2 mRNA was not increased in any of the cases with an immunohistochemical score of 2+. None of the 18 cases analyzed immunohistochemically scored as 0 or 1+ showed gene amplification; however, 7 cases showed chromosome 17 polysomy. Of the cases lacking biopsy tissue samples, 1 showed gene amplification in the smear (case 24).
Immunocytochemical Analysis
Immunocytochemical analysis was done in 46 cases. Both immunohistochemical and immunocytochemical analyses were done in 36 cases. There was complete agreement between immunohistochemical and immunocytochemical results in 23 cases (P < .001). Ten of the 13 cases with different scores had a difference of 1 point, while the other 3 had a difference of 2 points (cases 8, 28, and 33). In all 3 cases, immunohistochemical staining was scored as 2+, whereas immunocytochemical staining was scored as 0. Of the 8 cases scored immunohistochemically and immunocytochemically that had an immunohistochemical score of 3+, 7 had an immunocytochemical score of 3+ and 1 had an immunocytochemical score of 2+. Immunocytochemical analysis was difficult to interpret in smears with a lack of cellular cohesiveness because the cell membrane is damaged easily in single cells, making it difficult to assess the staining pattern. Interpretation of immunocytochemical analysis results was easier in smears with groups of cells, as shown in Images 3 and 7.
TaqMan RT-PCR RNA Relative Quantitation
RNA was extracted successfully from FNA material, and TaqMan RT-PCR for HER-2 mRNA was performed on 47 cases. There was at least a 2-fold increase in the HER-2 mRNA expression levels in 10 of 47 cases, and 8 of these had an immunohistochemical score of 3+. Of the 10 cases, 9 showed HER-2 gene amplification, with ratios from 2.5 to 7.5.
Case 2 had almost a 3-fold increase of mRNA compared with the calibrator but showed no amplification with FISH and had an immunocytochemical score of 2+. No biopsy material was available for immunohistochemical analysis or DNA assay. Case 15 was highly amplified and had immunohistochemical and immunocytochemical scores of 3+ and a high DNA assay, but the mRNA was near normal, at 1.06. Case 28 was amplified and had an immunocytochemical score of 2+ and slightly increased DNA at 2.28 (cutoff 2.0), but the mRNA was low, at 0.13. The TaqMan results for the nonamplified cases were lower than the calibrator in most cases in this material. There was no material available to do a FISH analysis of the calibrator. However, because this analysis is a relative quantification of HER-2, the results are still valid.
PCR-DNA Assay
DNA was extracted successfully from paraffin blocks in 34 cases. The PCR HER-2 DNA assay results were positive (ratio of HER-2 to the reference gene to the calibrator, >2) in 17 of 34 cases. Slight increases in DNA levels (>2 but <3) were seen in 5 cases without gene amplification, although 2 were polysomic. Another 2 cases of chromosome 17 polysomy without amplification gave even higher scores (5.43 and 3.31). The 9 cases scoring 3+ on immunohistochemical analysis also achieved high scores in the DNA assay (4.93-50.61).
Discussion
HER-2 is an important biologic marker in breast cancer. High-grade gene amplification is associated with protein overexpression, aggressive tumor behavior, and shortened survival.
It also has been shown to be an independent prognostic factor in breast cancer. 4, 6 The anti-HER-2 monoclonal ❚Image 1❚ Grade 2 invasive ductal carcinoma (H&E, ×400). ❚Image 2❚ Grade 2 invasive ductal carcinoma; immunohistochemical score, 1+ (×400).
antibody, trastuzumab, has shown therapeutic benefits alone and in combination with chemotherapy. Careful selection of patients likely to benefit from treatment with trastuzumab is important. It has been shown that patients with HER-2 overexpression of 2+ and 3+ on immunohistochemical staining benefit from treatment, with the 3+ subset showing the greatest benefit. 24 However, concern has been expressed about the accuracy of immunohistochemical analysis, particularly regarding the 2+ category. It has been suggested that HER-2 underexpression might be due to deletion and also might be associated with a poor prognosis. 25 HER-2 can be demonstrated by means of Southern blot, slot blotting, PCR, in situ hybridization, FISH, immunocytochemical analysis, and immunohistochemical analysis. However, discordance between detection methods has been seen by some investigators, particularly between immunohistochemical results on paraffin-embedded specimens and gene amplification results from the same tumors, 18, [26] [27] [28] whereas others have cited quite high concordance (90%). 29 In addition, the specificity of the interpretation of immunohistochemical staining results has been questioned. 30 HER-2 gene amplification has been shown to correlate with expression in 92% of cases. 31 The remaining ❚Image 3❚ Grade 2 invasive ductal carcinoma; immunocytochemical score, 1+ (×400).
❚Image 4❚ Grade 2 invasive ductal carcinoma; fine-needle aspiration smear; fluorescence in situ hybridization ratio, 1.0 (×1,000).
❚Image 5❚ Grade 3 invasive ductal carcinoma (H&E, ×400).
❚Image 6❚ Grade 3 invasive ductal carcinoma; immunohistochemical score, 3+ (×400).
subset of cases showing apparent discrepancies in amplification, transcription, and expression also could be explained by transcriptional dysregulation, 31 chromosome 17 polysomy, or simply "oversensitive" immunostaining, possibly owing to the use of polyclonal antibodies as opposed to monoclonal antibodies. 18 In the present study, we performed immunocytochemical analysis with the HercepTest kit. We were unable to demonstrate that immunocytochemical analysis is more sensitive than immunohistochemical analysis as described by others. 32 There was good correlation between 3+ immunostaining on the FNA smears and amplification of the HER-2 gene as demonstrated by FISH, implying that immunocytochemical analysis might be as useful as immunohistochemical analysis in identifying this group of patients. However, cases scored as 2+ immunohistochemically and those scored 2+ immunocytochemically will require further study with FISH.
We looked at gene amplification relative to chromosome copy number by means of FISH performed on FNA smears from 49 cases of breast carcinoma. FISH performed on whole nuclei gives the most accurate estimates of gene and chromosome copy numbers because truncation artifacts are avoided, resulting in accurate gene/chromosome ratios. 23 This might not be crucial with regard to HER-2 gene copy number because, in cases with significant amplification, the gene copy number is more than 10. 5 However, truncation might result in a significant underestimation of chromosome copy number, leading to an underestimation of chromosome polysomy and, in some cases, a falsely high amplification ratio. Immunohistochemical and immunocytochemical scores of 2+ or apparent low-level amplification often are associated with chromosome 17 polysomy and can be confirmed easily by using a combined chromosome and probe set. 33 In our experience, FNA smears obtained routinely at the Breast Diagnostic Center are ideal for FISH. Others have used imprint cytology from fresh tumor tissue after surgery with equal success. Because HER-2 gene amplification is correlated closely with protein expression in breast carcinoma, we regard the optimal FISH gene/chromosome ratio as the "gold standard" for HER-2 quantification in these tumors. In the present study, FISH ratios of more than 2.0 were seen in 11 cases, 9 of which scored 3+ in immunohistochemical analysis. Of the remaining 2 cases, 1 scored 2+ in immunohistochemical analysis and the other scored 2+ in immunocytochemical analysis. No cases without amplification scored 3+ in immunohistochemical analysis.
The pattern of FISH signal distribution most commonly seen in this material for the HER-2 gene was clustering, indicating intrachromosomal amplification or homogeneously staining regions, as opposed to double minutes indicating extrachromosomal amplification. Distinction between amplification patterns might have therapeutic significance in the future. 34 ❚Image 8❚ Grade 3 invasive ductal carcinoma; fine-needle aspiration smear; fluorescence in situ hybridization ratio, 7.5 (×1,000).
immunohistochemically negative tumors, indicating that FISH is a better predictor of survival than immunohistochemical analysis. About 6% of FISH-negative breast cancers are immunohistochemically positive, however, and survival of the patients is similar to that of patients with FISH-negative, immunohistochemically negative tumors. 17 Few articles are published on the estimation of HER-2 in routine FNA smears from breast cancer by means of FISH, although FISH has been shown to be eminently suitable for use on FNA material. [35] [36] [37] We also have estimated HER-2 DNA and mRNA by means of PCR relative quantification. When comparing the commercially available DNA assay used in the present study and the RNA assay, it is important to realize that both are relative quantitation methods and that the calibrators differ, as do the housekeeping genes used. The resultant quantities have no direct relationship to each other. We found that the DNA assay gave slightly increased levels in cases of chromosome polysomy. These cases would require further study with FISH. We extracted intact RNA from air-dried, frozen FNA smears and performed TaqMan RT-PCR relative quantification for HER-2, showing that even small amounts of FNA material stored over time can be used for this purpose. We found good correlation between the TaqMan PCR and FISH results, although there were apparent discrepancies in amplification, transcription, and expression in cases 2, 15, and 28. Case 2 showed increased mRNA and protein expression despite the lack of gene amplification. This could be explained by technical considerations such as failure of the FISH method. But, as suggested by Pauletti et al, 17 it also might have a biologic explanation in that transcriptional activation of the HER-2 gene might occur without amplification, even though HER-2 gene amplification has been shown to correlate with expression in more than 92% of cases. The low HER-2 mRNA levels in cases 15 and 28 serve to demonstrate that amplification is not necessarily reflected in raised mRNA levels.
Conclusion
FISH was performed successfully on FNA smears obtained routinely at the Breast Diagnostic Center. FISH performed on whole nuclei correlates well with FISH performed on tissue sections, although FNA might give more accurate results. 36 A staining intensity of 3+ in immunohistochemical and immunocytochemical analyses corresponds to a FISH ratio of more than 2.5. Immunohistochemical and immunocytochemical scores of 2+ and 1+ are not necessarily associated with gene amplification. Increased DNA PCR ratios might be seen without amplification, reflecting polysomy. TaqMan mRNA relative quantity scores correlated well with HER-2 amplification. However, owing to the ease with which it can be performed and interpreted, we conclude that FISH is the test of choice for HER-2 estimation; it can be used primarily or to confirm the results of immunohistochemical and immunocytochemical analyses and PCR. 38, 39 
